Protara Therapeutics, Inc. (NASDAQ:TARA) Receives $22.50 Consensus Target Price from Brokerages
Protara Therapeutics, Inc. (NASDAQ:TARA – Get Free Report) has earned an average rating of “Buy” from the six analysts that are currently covering the firm, Marketbeat.com reports. Six investment analysts have rated the stock with a buy rating. The average 12-month price target among analysts that have covered the stock in the last year is […]
Protara Therapeutics, Inc. (NASDAQ:TARA – Get Free Report) has earned an average rating of “Buy” from the six analysts that are currently covering the firm, Marketbeat.com reports. Six investment analysts have rated the stock with a buy rating. The average 12-month price target among analysts that have covered the stock in the last year is […]